{"id":21690,"date":"2025-04-08T10:04:43","date_gmt":"2025-04-08T08:04:43","guid":{"rendered":"https:\/\/www.fbg.ub.edu\/?p=21690"},"modified":"2025-04-08T10:04:43","modified_gmt":"2025-04-08T08:04:43","slug":"la-spin-off-accure-therapeutics-recibe-16-millones-de-dolares-para-ensayos-clinicos-de-un-innovador-farmaco-contra-el-parkinson","status":"publish","type":"post","link":"https:\/\/www.fbg.ub.edu\/es\/actualidad\/la-spin-off-accure-therapeutics-recibe-16-millones-de-dolares-para-ensayos-clinicos-de-un-innovador-farmaco-contra-el-parkinson\/","title":{"rendered":"La spin-off Accure Therapeutics recibe 1,6 millones de d\u00f3lares para ensayos cl\u00ednicos de un innovador f\u00e1rmaco contra el Parkinson"},"content":{"rendered":"<p class=\"\" data-start=\"1688\" data-end=\"1952\">La spin-off de la <a href=\"https:\/\/web.ub.edu\/web\/ub\/\" target=\"_blank\" rel=\"noopener\">Universidad de Barcelona<\/a> (UB), <a href=\"https:\/\/accure.health\/\" target=\"_blank\" rel=\"noopener\"><strong data-start=\"1737\" data-end=\"1760\">Accure Therapeutics<\/strong><\/a>, ha recibido dos subvenciones por un total de <strong data-start=\"1807\" data-end=\"1834\">1,6 millones de d\u00f3lares<\/strong> para impulsar el desarrollo cl\u00ednico de su f\u00e1rmaco <strong data-start=\"1885\" data-end=\"1895\">ACT-02<\/strong>, destinado al tratamiento de la enfermedad de Parkinson.<\/p>\n<p class=\"\" data-start=\"1954\" data-end=\"2195\">Se trata de un activo innovador con potencial de modificaci\u00f3n de la enfermedad que inhibe la prolil-endopeptidasa (PREP), una prote\u00edna previamente poco explorada para la enfermedad de Parkinson, pero que presenta un potencial prometedor.<\/p>\n<p class=\"\" data-start=\"2197\" data-end=\"2425\">El programa <strong data-start=\"2209\" data-end=\"2219\">ACT-02<\/strong> se encuentra en una fase precl\u00ednica avanzada y est\u00e1 respaldado por datos positivos de eficacia en modelos de Parkinson in vivo, as\u00ed como por un conjunto de datos toxicol\u00f3gicos y de seguridad farmacol\u00f3gica.<\/p>\n<p class=\"\" data-start=\"2427\" data-end=\"2760\">Las ayudas, otorgadas por <strong data-start=\"2453\" data-end=\"2486\">The Michael J. Fox Foundation<\/strong> y <strong data-start=\"2489\" data-end=\"2523\">Fonds National de la Recherche<\/strong>, suponen un hito importante para la spin-off de la UB, que refuerza la solidez cient\u00edfica de ACT-02, los planes de I+D asociados a este y su potencial para abordar necesidades m\u00e9dicas cr\u00edticas no cubiertas hasta ahora para el Parkinson.<\/p>\n<p class=\"\" data-start=\"2762\" data-end=\"2969\">&lt;&lt; <a class=\"\" href=\"https:\/\/mailchi.mp\/ala.associates\/accure-therapeutics-recibe-16-millones-de-dlares-en-dos-subvenciones-para-llevar-a-ensayos-clnicos-un-innovador-frmaco-contra-el-parkinson?e=b2866d7c48\" target=\"_new\" rel=\"noopener\" data-start=\"2765\" data-end=\"2969\">M\u00e1s informaci\u00f3n<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La spin-off de la Universidad de Barcelona (UB), Accure Therapeutics, ha recibido dos subvenciones por un total de 1,6 millones&#8230;<\/p>\n","protected":false},"author":2,"featured_media":21685,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-21690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualidad"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/posts\/21690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=21690"}],"version-history":[{"count":2,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/posts\/21690\/revisions"}],"predecessor-version":[{"id":21695,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/posts\/21690\/revisions\/21695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media\/21685"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=21690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=21690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=21690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}